Baseline characteristics at diagnosis of 150 patients with FLT3-mutated AML in R/R setting
| . | Total, N = 150 (100%) . | ICT + MIDO, n = 54 (36%) . | ICT, n = 96 (64%) . | P value . |
|---|---|---|---|---|
| Age at diagnosis (y) | .09 | |||
| Median (IQR) | 51.0 (43.0-57.0) | 52.5 (47.0-62.0) | 50.0 (41.5-55.0) | |
| Range | 18.0-76.0 | 23.0-76.0 | 18.0-73.0 | |
| Sex, n (%) | .08 | |||
| Male | 72 (48.0) | 31 (57.4) | 41 (42.7) | |
| Female | 78 (52.0) | 23 (42.6) | 55 (57.3) | |
| AML status, n (%) | .5 | |||
| De novo | 134 (89.3) | 47 (87.0) | 87 (90.6) | |
| Secondary AML | 16 (10.7) | 7 (13.0) | 9 (9.4) | |
| WBC at diagnosis (×109/L) | .5 | |||
| Median (IQR) | 43.6 (12.1-110.0) | 52.0 (15.5-120.9) | 36.5 (12.0-110.0) | |
| Range | 0.9-458.0 | 0.9-458.0 | 1.1-368.8 | |
| Blasts BM (%) | .4 | |||
| Median (IQR) | 81.0 (57.0-89.0) | 82.0 (61.0-91.0) | 76.5 (51.5-89.0) | |
| Range | 15.0-99.0 | 15.0-99.0 | 19.0-98.0 | |
| Blasts PB (%) | .3 | |||
| Median (IQR) | 62.0 (26.0-87.0) | 68.0 (36.0-89.0) | 57.0 (16.0-85.5) | |
| Range | 0.0-98.0 | 3.0-97.0 | 0.0-98.0 | |
| ELN 2022 prognosis, n (%) | .07 | |||
| Favorable | 14 (9.3) | 6 (11.1) | 8 (8.3) | |
| Intermediate | 98 (65.3) | 29 (53.7) | 69 (71.9) | |
| Adverse | 38 (25.3) | 19 (35.2) | 19 (19.8) | |
| FLT3-ITD, n (%)∗ | .08 | |||
| Mutation | 130 (86.7) | 43 (79.6) | 87 (90.6) | |
| No mutation | 20 (13.3) | 11 (20.4) | 9 (9.4) | |
| FLT3-TKD, n (%)∗ | .12 | |||
| Mutation | 26 (17.3) | 13 (24.1) | 13 (13.5) | |
| No mutation | 124 (82.7) | 41 (75.9) | 83 (86.5) | |
| NPM1, n (%)∗ | .4 | |||
| Mutation | 82 (54.7) | 27 (50.0) | 55 (57.3) | |
| No mutation | 68 (45.3) | 27 (50.0) | 41 (42.7) |
| . | Total, N = 150 (100%) . | ICT + MIDO, n = 54 (36%) . | ICT, n = 96 (64%) . | P value . |
|---|---|---|---|---|
| Age at diagnosis (y) | .09 | |||
| Median (IQR) | 51.0 (43.0-57.0) | 52.5 (47.0-62.0) | 50.0 (41.5-55.0) | |
| Range | 18.0-76.0 | 23.0-76.0 | 18.0-73.0 | |
| Sex, n (%) | .08 | |||
| Male | 72 (48.0) | 31 (57.4) | 41 (42.7) | |
| Female | 78 (52.0) | 23 (42.6) | 55 (57.3) | |
| AML status, n (%) | .5 | |||
| De novo | 134 (89.3) | 47 (87.0) | 87 (90.6) | |
| Secondary AML | 16 (10.7) | 7 (13.0) | 9 (9.4) | |
| WBC at diagnosis (×109/L) | .5 | |||
| Median (IQR) | 43.6 (12.1-110.0) | 52.0 (15.5-120.9) | 36.5 (12.0-110.0) | |
| Range | 0.9-458.0 | 0.9-458.0 | 1.1-368.8 | |
| Blasts BM (%) | .4 | |||
| Median (IQR) | 81.0 (57.0-89.0) | 82.0 (61.0-91.0) | 76.5 (51.5-89.0) | |
| Range | 15.0-99.0 | 15.0-99.0 | 19.0-98.0 | |
| Blasts PB (%) | .3 | |||
| Median (IQR) | 62.0 (26.0-87.0) | 68.0 (36.0-89.0) | 57.0 (16.0-85.5) | |
| Range | 0.0-98.0 | 3.0-97.0 | 0.0-98.0 | |
| ELN 2022 prognosis, n (%) | .07 | |||
| Favorable | 14 (9.3) | 6 (11.1) | 8 (8.3) | |
| Intermediate | 98 (65.3) | 29 (53.7) | 69 (71.9) | |
| Adverse | 38 (25.3) | 19 (35.2) | 19 (19.8) | |
| FLT3-ITD, n (%)∗ | .08 | |||
| Mutation | 130 (86.7) | 43 (79.6) | 87 (90.6) | |
| No mutation | 20 (13.3) | 11 (20.4) | 9 (9.4) | |
| FLT3-TKD, n (%)∗ | .12 | |||
| Mutation | 26 (17.3) | 13 (24.1) | 13 (13.5) | |
| No mutation | 124 (82.7) | 41 (75.9) | 83 (86.5) | |
| NPM1, n (%)∗ | .4 | |||
| Mutation | 82 (54.7) | 27 (50.0) | 55 (57.3) | |
| No mutation | 68 (45.3) | 27 (50.0) | 41 (42.7) |
ELN, European LeukemiaNet; IQR, interquartile range; PB, peripheral blood; WBC, white blood cells.
Status assessed by FA.